Ghanshyam Mali
The use of glucagon-like peptide-1 (GLP-1) analogues has been linked with the risk of pancreatic and thyroid cancer. Exenatide and liraglutide carry a boxed warning in their pack insert regarding the possible association with medullary thyroid cancer and caution regarding acute pancreatitis. Our objective was to detect from EudraVigilance database, a signal of pancreatic and thyroid cancer with exenatide and liraglutide treatments in patients with diabetes.
Methods: Herein, we analyzed all spontaneous cases of pancreatic and thyroid cancer reported with exenatide and liraglutide in EudraVigilance database from their inception till 30th January 2020. A case/noncase method was used to detect the association, calculating proportional reporting ratios (PRRs) and their 95% confidence interval (CI) as a measure of disproportionality.
Results: There were 4349 cases of pancreatic cancer and 1697 cases of thyroid cancer in the 6,665,794 reports recorded in EudraVigilance during the study period. From the inception of exenatide and liraglutide, the total numbers of pancreatic cancer cases identified with them in EudraVigilance database were 222 and 313, respectively, and the total numbers of thyroid cancer cases were 36 and 53, respectively. Significant disproportionality was observed between pancreatic cancer and exenatide and liraglutide with PRR of 36.4 (95% CI, 31.8-41.7) and 42.4 (95% CI, 37.7- 47.6), respectively. Disproportionality was also observed between thyroid cancer and exenatide and liraglutide with PRR of 14.7 (95% CI, 10.5-20.4) and 17.6 (95% CI, 13.4-23.2), respectively.
Conclusions: This study based on EudraVigilance database further confirms signals for both thyroid and pancreatic cancer with exenatide and liraglutide.
